Evidence map›Paper›PMID 39143094›Full record

ArticleNature communications2024

Transition from Kwon [4+2]- to [3+2]-cycloaddition enabled by AgF-assisted phosphine catalysis.

Jinlong Qian, Lijin Zhou, Yuyi Wang, Xiaoyu Zhou, Xiaofeng Tong

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinlong QianSchool of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou, Zhejiang, 318000, China.ORCID http://orcid.org/0000-0003-0390-848X
Lijin ZhouSchool of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou, Zhejiang, 318000, China.ORCID http://orcid.org/0009-0003-2694-2346
Yuyi WangSchool of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou, Zhejiang, 318000, China.ORCID http://orcid.org/0009-0007-7604-4033
Xiaoyu ZhouSchool of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou, Zhejiang, 318000, China. zhouxiaoyu@tzc.edu.cn.ORCID http://orcid.org/0000-0002-3552-3595
Xiaofeng TongSchool of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou, Zhejiang, 318000, China. xftong@tzc.edu.cn.ORCID http://orcid.org/0000-0002-6789-1691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphine catalysis generally relies on the potential of carbanion-phosphonium zwitterions that are generated via nucleophilic addition of phosphine catalyst to electrophilic reactants. Consequently, structural modification of zwitterions using distinct electrophilic reactants has emerged as a prominent strategy to enhance catalysis diversity. Herein, we present an alternative strategy that utilizes AgF additive to expand phosphine catalysis. We find that AgF can readily transform the canonical carbanion-phosphonium zwitterion into silver enolate-fluorophosphorane intermediate, eventually furnishing a P(III)/P(V) catalytic cycle. This strategy has been successfully applied to the phosphine-catalyzed reaction of 2-substituted allenoate and imine, resulting in the transition from Kwon [4 + 2] cycloaddition to [3 + 2] cycloaddition. This [3 + 2] cycloaddition features remarkable diastereoselectivity, high yield, and broad substrate scope. Experimental and computational studies have validated the proposed mechanism. Given the prevalence of carbanion-phosphonium zwitterions in phosphine catalysis, this AgF-assisted strategy is believed to hold significant potential for advancing P(III)/P(V) catalysis.

Identifiers

PMID39143094
PMCPMC11324788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.